Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Acute Myeloid Leukemia Clinical Trial

Official title:

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02890758
• Other study ID #: CASE2Z16
• Status: Completed
• Phase: Phase 1
• Start date: May 22, 2018
• Est. completion date: February 17, 2023

Study information

• Verified date: February 2023
• Source: Case Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find the number of natural killer (NK) cells from non-HLA matched donors that can be safely infused into patients with cancer. NK cells are a form of lymphocytes that defend against cancer cells. NK cells in cancer patients do not work well to fight cancer. In this study, the NK cells are being donated by healthy individuals without cancer who are not "matched" by human leukocyte antigen (HLA) genes to patients. After receiving these NK cells, patients may also be given a drug called ALT803. ALT803 is a protein that keeps NK cells alive, helps them grow in number and supports their cancer-fighting characteristics. HLA-unmatched NK cell infusion is investigational (experimental) because the process has not approved by the Food and Drug Administration (FDA).

Description:

Primary Objective: To determine the maximum tolerated dose (MTD) of ex vivo expanded non-HLA matched donor NK cells in combination with ALT-803 Secondary Objectives: - Describe safety profile / toxicity of combining ALT-803 with NK cell adoptive therapy. - Determine antitumor activity of allogeneic NK cells with ALT-803 support. - Determine if a lymphocyte depleting regimen is adequate for preventing early elimination of HLA-mismatched donor NK cells by host T-cells. Study Design: This is a phase I study with "3+3" design with three planned dose levels of NK cells and a fixed dose of ALT-803. Three patients will be enrolled sequentially to each dose level, starting with dose level 1. Patients will be segregated to either receive ALT803 as cytokine support after NK cell infusion (starting with same dose level as Level 1) or no cytokine administration. Patients in the arm receiving ALT803 will be either hematologic malignancy patients (Cohort A) or Colon/Soft tissue sarcoma patients (Cohort B). Absence of dose limiting toxicity (DLT) in the DLT assessment period of 28 days must be documented for all patients enrolled a cell dose without ALT803 before the next cohort of patients to receive cytokines at that dose level can be enrolled. Patients can also be enrolled in parallel to the next cell dose level without cytokines.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: February 17, 2023
• Est. primary completion date: June 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have histologic confirmation of relapsed and or refractory hematologic malignancy, locally advanced or metastatic colon/rectal carcinoma, or refractory and/or relapsed soft tissue sarcomas and have failed at least one standard line of therapy.
• Patients will be eligible if they have either declined standard treatment regimens or if there is no standard approach to curative salvage therapy per National Comprehensive Cancer Network (NCCN) guidelines in the setting of relapsed/refractory disease.
• In addition, patients for whom a potential 29-day delay in treatment will not interfere with the subject's potential therapeutic options can be eligible per the treating physician's discretion.

Malignancies can include:

• Acute myeloid leukemia
• Myelodysplastic syndrome
• Acute lymphoblastic leukemia
• Chronic myeloid leukemia
• Chronic lymphocytic leukemia
• Non Hodgkin Lymphoma
• Hodgkin Lymphoma
• Myeloproliferative syndromes
• Plasma cell myeloma
• Colon/rectal carcinoma
• Soft tissue sarcomas including but not limited to Ewing's sarcoma and Rhabdomyosarcoma
• Patients must have recovered from acute toxicities of prior chemotherapy or stem cell transplant. Any prior non-hematologic vital organ toxicity (cardiac, pulmonary, hepatic, renal) of previous therapy must have resolved to grade 1 or less.
• All previous chemotherapy or radiation must be completed at least 3 weeks prior to study entry. Immunologic therapy must be completed at least 3 weeks prior to study entry. Patients with prior stem cell transplant must be greater than 365 days post-transplant.
• Eastern Cooperative Oncology Group (ECOG) performance status =2
• Organ function criteria (There is no exclusion for the presence of cytopenias),
• Serum total bilirubin <2 mg/dl (except if known Gilbert syndrome and normal transaminases)
• Aspartate aminotransferase (AST) (SGOT) < 2.5 X institutional upper limit of normal
• Alanine aminotransferase (ALT) (SGPT) < 2.5 X institutional upper limit of normal
• Pulmonary function (DLCO) >40% of the expected value corrected for alveolar volume and hemoglobin
• Serum Creatinine = 1.5 X institutional upper limit of normal
• Subjects must have the ability to understand and the willingness to sign a written informed consent document.
• Women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry and for the duration of study participation. Women of child-bearing age must have documented negative pregnancy test prior to start of lympho-depleting regimen.

Exclusion Criteria:

• Subjects receiving any other investigational agents.
• Subjects for whom a potential 29-day delay in treatment will interfere with the subject's potential therapeutic options.
• Patients with untreated malignant involvement of the central nervous system (CNS) should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Head imaging will be necessary to document absence of CNS involvement in patients with colon/rectal cancer and soft tissue sarcomas. Patients with hematologic malignancies who have undergone treatment for malignant involvement of the CNS must have no evidence of residual disease by imaging or CSF sampling prior to study enrollment.
• History of allergic reactions to chemotherapy agents used in this protocol as part of lymphodepletion regimen (Fludarabine and Cyclophosphamide)
• Patients with uncontrolled intercurrent illness including, but not limited to ongoing active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant or breastfeeding women are excluded from this study.
• HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with chemotherapeutic agents. In addition, these patients are at increased risk of lethal infections when treated with marrow suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
• Chronic active untreated hepatitis B or C infection.
• Recipients of previous allogeneic transplants who have rash involving more than 10% body surface area attributed to graft versus host disease (GVHD) (> Grade 1 GVHD of skin). Stem cell transplant recipients will be excluded if they are still receiving immunosuppression including steroids for GVHD or have active GVHD in any organ (except for Grade 1 only of skin, not requiring treatment).

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Adenocarcinoma of Rectum
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Colon Carcinoma
• Ewing's Sarcoma
• Hodgkin Lymphoma
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndrome
• Myelodysplastic Syndromes
• Myeloproliferative Syndromes
• Non Hodgkin Lymphoma
• Plasma Cell Myeloma
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Rhabdomyosarcoma
• Sarcoma
• Sarcoma, Ewing
• Soft Tissue Sarcoma
• Syndrome

Intervention

Biological:
• Natural Killer (NK) Cells
Dose escalation of Natural Killer (NK) Cells from two infusion of starting at Dose Level 1 (1x10^7 cells/kg), dose Level-1 (1x10^6 cells/kg) if 2 of 6 patients at Level 1 develop DLTs. Escalation to dose level 2 (2.5X10^7) and Dose level 3 (5X10^7) is dependent on DLT
• ALT803
given at 6mcg/kg weekly for four weeks

Locations

Country	Name	City	State
United States	University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Brenda Cooper, MD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD of ex vivo expanded non-HLA matched donor NK cells in combination with ALT-803	MTD Will be determined by dose limiting toxicity (DLT). The MTD will be defined as the dose level immediately below that at which 2 of 6 subjects experience a dose limiting toxicity.	Up to 28 days
Primary	Number of participants without Graft Versus Host Disease (GVHD)	Measure of safety of natural killer (NK) cells in the absence of HLA matching	up to 28 days after beginning treatment
Secondary	Number of patients with hematological response	Complete Remission (CR): Bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count >1.0x10^9/L; platelet count >100x10^9/L.; CR with incomplete recovery (CRi): All CR criteria except residual neutropenia or thrombocytopenia.; Partial Remission (PR):Hematologic criteria of CR; decrease of bone marrow blast percentage to 5-25%; and decrease of pretreatment bone marrow blast percentage by =50%.; Cytogenetic CR (CRc): Reversion to normal karyotype at the time of morphologic CR.; Resistant disease (RD): Failure to achieve CR, CRi, or PR. Death in aplasia: Deaths occurring =7 days after initial treatment. Death from indeterminate cause: Deaths before completing therapy, or <7 days following completion; or deaths occurring =7 days after therapy with no blasts in the blood Relapse: Bone marrow blasts = 5%; or reappearance of blasts in the blood; or development of extramedullary disease	Up to 12 months after beginning treatment
Secondary	Patients response for radiographically measurable lesions	Measurable disease: at least one measurable lesion.; Measurable lesions: those that can be measured in at least one dimension as >20 mm with conventional techniques or as >10 mm with spiral CT scan.; Non-measurable lesions: all other lesions, including small lesions that are not confirmed and followed by imaging techniques.; Baseline documentation of "Target" lesions: all measurable lesions up to a maximum of five lesions per organ and 10 lesions in total. Target lesions should be selected on the basis of their size and their suitability for accurate repeated measurements.; Non-target lesions: all other lesions should be identified as non-target lesions. Non-target lesions include measurable lesions that exceed the maximum numbers per organ or total of all involved organs as well as non-measurable lesions.	Up to 12 months after beginning treatment
Secondary	Patients with malignant lymphoma response	Lymphoma response of Complete remission, partial remission, relapsed disease, stable disease, progressive disease and best response based on the Journal of Clinical Oncology criteria defined by Cheson in 2014	Up to 12 months after beginning treatment
Secondary	Patients response for Waldenstrom's macroglobulinemia (WM)	Complete response (CR): complete disappearance of disease at and negative serum immunofixation.; Partial response (PR): >50% reduction of serum monoclonal protein concentration with >50% reduction of tumor infiltrate and resolution of symptoms attributable to WM.; Minor response (MR): > 25% but l<50% reduction of serum monoclonal immunoglobulin M (IgM) determined by protein electrophoresis and no new symptoms or signs of active disease.; Stable disease: < 25% reduction and <25% increase of serum monoclonal IgM without progression of adenopathy, organomegaly, cytopenias, or clinically significant symptoms caused by disease and/or signs of WM.; Progressive disease: fails to meet criteria for response or stable disease. Progression also requires at least a 25% increase of serum monoclonal protein from the lowest value or worsening of cytopenias, lymphadenopathy, or organomegaly, or appearance of disease-related complications.	Up to 12 months after beginning treatment
Secondary	Patients response for cutaneous lymphomas	CR/CCR; Complete resolution of skin patches, plaques and tumors (or erythroderma); No evidence of abnormal lymph nodes; Absence of circulating Sézary cells; No evidence of new tumor (CCR) plus confirmation by skin biopsy (CR) PR; =50% improvement in the summation of (? Skin + ? Lymph Node + ? Peripheral Blood) with at least =30% improvement in ? Skin; No worsening in Lymph Node or Sézary cells; No evidence of new tumors (cutaneous or non-cutaneous); Stable Disease at 90 Days (SD90); • Fails to meet criteria for PR or CR but absence of new cutaneous or non-cutaneous disease over 90 days; Progressive Disease (PD); = 50% increase from nadir or baseline in styrylpyridine derivative (SPD) or any node or lesion; = 50% increase from nadir in gestational trophoblastic disease (GTD) of any node previously >1cm in shortest diameter; Appearance of any new cutaneous or non-cutaneous lesion during or at the end of therapy.	Up to 12 months after beginning treatment
Secondary	Patients response for multiple myeloma	Stringent Complete Response (sCR); CR as defined below plus: • Normal FLC ratio and Absence of clonal cells in bone marrow CR; Negative immunofixation on the serum and urine and: Disappearance of any soft tissue plasmacytomas; =5% plasma cells in bone marrow Very good partial response (VGPR); Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level <100mg per 24h PR; = 50% reduction of serum M-protein and reduction in 24-h urinary M-protein by = 90% or to <200 mg per 24h; If the serum and urine protein are unmeasurable, = 50% decrease in the difference between involved and uninvolved FLC levels is required; If the serum and urine protein are unmeasurable, and serum free light assay is also unmeasurable, = 50% decrease in plasmacells is required SD; Not meeting criteria for CR, VGPR, PR, or progressive disease	Up to 12 months after beginning treatment
Secondary	Patients response for chronic myeloid leukemia (CML)	Complete hematologic response; • White blood cell count <10,000/microL with no immature granulocytes and <5 percent basophils on differential, platelet count <450,000/microL, and spleen not palpable.; Cytogenetic responses; Complete cytogenetic response: No Philadelphia chromosome positive cells present.; Partial cytogenetic response: 1 to 35 percent Philadelphia chromosome positive cells present.; Major cytogenetic response includes patients with complete and partial cytogenetic response (ie, 0 to 35 percent Philadelphia chromosome positive cells present).; Minor-minimal cytogenetic response: 36 to 95 percent Philadelphia chromosome positive cells present.; Molecular response: Complete molecular response: break cluster region - Abelson family kinases (BCR-ABL) transcript nondetectable and nonquantifiable in an assay that has at least 4 to 5 log range.; Major molecular response: An at least three log reduction in BCR-ABL transcript levels from baseline.	Up to 12 months after beginning treatment
Secondary	Patients response for metastatic colon/rectal carcinoma and soft tissue sarcomas	Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm (the sum may not be "0" if there are target nodes). Partial Response: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.; Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions may be considered progression).; Stable Disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study.	Up to 12 months after beginning treatment
Secondary	Average duration of response	The duration of overall response is measured from the time of NK Cell infusion until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).	Up to 12 months after beginning treatment
Secondary	Average duration of Overall Survival	Overall survival is measured from the date of first infusion of NK cells to the date of death from any cause; patients not known to have died at last follow up are censored on the date they were last known to be alive.	Up to 12 months after beginning treatment
Secondary	Average duration of relapse free survival	Only those patients achieving complete response (CR) or complete response with incomplete recovery (CRI). It is measured from the date of infusion of NK cells until the date of relapse or death from any cause; patients not known to have relapsed or died at last follow up are censored on the date they were last examined.	Up to 12 months after beginning treatment
Secondary	in vivo Natural Killer (NK) levels	Measurement of in vivo NK cell levels following cell product infusion will be done on peripheral blood by flow cytometry (CD3- CD56+ positive cells). This will be done on peripheral blood samples of patients. Measurement of successful donor NK cell persistence (absence of cell product rejection) will be defined as measurement of >100 NK cell/µL	up to 28 days after beginning treatment